Confirm a stable target identifier before relying on this context across project surfaces.
CHEMBL345 Target Snapshot
Nucleic Acid · NUCLEIC-ACID
Research home keeps recent targets
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Switch target
Move to another high-traffic target or paste a specific ChEMBL target ID.
Frame the target before identity details
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Confirm a stable target identifier before relying on this context across project surfaces.
Nucleic Acid
Review this target as Nucleic Acid.
Protein source · UniProt accession via ChEMBL component mappingCross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Nucleic Acid as ChEMBL target CHEMBL345. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Start with the right source
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Nucleic Acid still has a stable protein naming contract across sources.
Jump to Protein ContextUse this block first when you need the strongest disease program and evidence level in one place.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardBasic Information
Verify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Nucleic Acid |
| Target Type | NUCLEIC-ACID |
| Organism | None |
Next Actions
UniProt Target Context
Reviewable protein naming and mapping context for this target snapshot.
How to read this target
Review this target as Nucleic Acid.
Clinical Phase Distribution
Activity Type Distribution
Top Inhibitors (by pChEMBL)
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL3627920 | 10.82 | Kd | 0.015 | Preclinical |
| CHEMBL298359 | 10.28 | IC50 | 0.052 | Clinical |
| CHEMBL340601 | 10.0 | Kd | 0.1 | Preclinical |
| CHEMBL75298 | 9.92 | IC50 | 0.12 | Preclinical |
| CHEMBL274951 | 9.89 | IC50 | 0.13 | Preclinical |
| CHEMBL72435 | 9.82 | IC50 | 0.15 | Preclinical |
| CHEMBL75775 | 9.8 | IC50 | 0.16 | Preclinical |
| CHEMBL48060 | 9.72 | IC50 | 0.19 | Preclinical |
| CHEMBL339539 | 9.7 | Kd | 0.2 | Preclinical |
| CHEMBL308944 | 9.68 | IC50 | 0.21 | Preclinical |
pChEMBL Value Distribution
Approved Drugs
Assay Landscape
Binding — 2,854 assays, 555 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| nucleic acid format | 2,698 | 546 | 5.7 |
| cell-based format | 131 | 2 | 7.5 |
| assay format | 20 | 7 | 6.8 |
| tissue-based format | 5 | 0 | — |
ADME — 1,464 assays, 0 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| organism-based format | 1,118 | 0 | — |
| nucleic acid format | 115 | 0 | — |
| tissue-based format | 108 | 0 | — |
| cell-free format | 95 | 0 | — |
| cell-based format | 22 | 0 | — |
| assay format | 5 | 0 | — |
| microsome format | 1 | 0 | — |
Functional — 349 assays, 375 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 311 | 297 | 5.8 |
| cell-based format | 25 | 78 | 7.3 |
| cell-free format | 9 | 0 | — |
| organism-based format | 3 | 0 | — |
| tissue-based format | 1 | 0 | — |
Unassigned — 41 assays, 0 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| organism-based format | 23 | 0 | — |
| cell-based format | 7 | 0 | — |
| tissue-based format | 6 | 0 | — |
| assay format | 3 | 0 | — |
| cell-free format | 2 | 0 | — |